SYMPOSIUM Antimicrobial resistance: a growing serious threat for global public health Play video Chairs: V. Di Pilato (Italy) G.M. Rossolini (Italy)
09.00 - 09.20	Global epidemiology of antimicrobial resistance in Gram-negatives A. Brink (South Africa)
09.20 - 09.40	Global epidemiology of antimicrobial resistance in Gram-positives - S. Stefani (Italy) Recording not authorized
09.40 - 10.00	Epidemiology (MBL, CRE) and burden of disease - Y. Carmeli (Israel)
10.00 - 10.20	The impact of new and rapid microbiological diagnostic test - G.M. Rossolini (Italy) Recording not authorized
10.20 - 10.40	Resistance in Candida and Aspergillus - M. Mikulska (Italy)
	LECTURE From past to future: 40 years of infectious disease insights Play video Speaker: E. Bouza (Spain)
	SYMPOSIUM From pathogen to patient pathway: addressing the challenges of an evolving fungal landscape Play video Chairs: Y. Carmeli (Israel), M. Bassetti (Italy)
14.15 - 14.30	Clinical impact of antifungal resistance - P. Muñoz (Spain)
14.30 - 14.45	Antifungal treatment: a future outlook - O. Cornely (Germany) Recording not authorized
14.45 - 15.00	Fungal endocarditis: unusual but devastating diseases - A. Vena (Italy)
15.00 - 15.15	Is one size fits all appropriate for antifungal treatment duration? - F.G. De Rosa (Italy) Recording not authorized
	SYMPOSIUM New and recent antibiotics in the pipeline Play video Chairs: Chairs: O. Cornely (Germany), D. Nicolau (USA)
16.15 - 16.30	Cefepime/taniborbactam - D.R. Giacobbe (Italy)
16.30 - 16.45	Cefepime/zidebactam - S. Corcione (Italy)
16.45 - 17.00	Eravacycline - C. Tascini (Italy)
17.00 - 17.15	Cefepime/enmetazobatcam - M. Tumbarello (Italy)
17.15 - 17.30	Aztreonam/avibactam - D. Nicolau (USA)
17.30 - 17.45	Sulbactam/durlobactam - A. Russo (Italy)
17.45 - 18.00	Cefiderocol/ xeruborbactam - M. Bartoletti (Italy)
17.45 - 18.00	Delafloxacin - A. Vena (Italy)
17.45 - 18.00	Phages and Microbiota - M. Peghin (Italy)
	SYMPOSIUM Which are the best treatment options for superbugs? Play video Chairs: Chairs: F.G. De Rosa (Italy), M. Tumbarello (Italy)
16.15 - 16.30	AmpC and ESBL’s including GES - C. Tascini (Italy)
16.30 - 16.45	KPC and OXA-48 - D.R. Giacobbe (Italy)
16.45 - 17.00	Pseudomonas aeruginosa - Y. Carmeli (Israel)
17.00 - 17.15	MBL - M. Bassetti (Italy)
17.15 - 17.30	Acinetobacter baumannii - G. Poulakou (Greece)
17.30 - 17.45	MRSA-VRE - M. Mikulska (Italy)

	SYMPOSIUM The best duration of antimicrobial treatment in different settings Play video Chairs: Chairs: P. Grossi (Italy), A. Torres (Spain)
09.00 - 09.15	Infective endocarditis - F.G. De Rosa (Italy)
09.15 - 09.30	Osteomyelitis and prosthetic infections - S. Tedeschi (Italy)
09.30 - 09.45	VAP and HAP - D. Koulenti (UK)
09.45 - 10.00	CAP - A. Torres (Spain)
09.45 - 10.00	Abdominal infections - M. Sartelli (Italy)
09.45 - 10.00	Bloodstream infections - M. Giannella (Italy)
09.45 - 10.00	Urinary tract infections - A. Mularoni (Italy)
	SYMPOSIUM Frequent mistakes and controversial issues in the choice of initial antibiotic therapy Play video Chairs: I. Gentile (Italy), P. Muñoz (Spain)
10.50 - 11.05	When microbiological results lead to inappropriate antibiotic prescriptions: the case of urine cultures, respiratory samples, and superficial swabs - P. Muñoz (Spain)
11.05 - 11.20	When empirical therapy is necessary and when not? - J.F. Timsit (France)
11.20 - 11.35	Can broad-spectrum empirical therapy be avoided in patients not colonized by MDR pathogens? A. Soriano (Spain)
11.35 - 11.50	Combination therapy for Gram-negative infections: when, how and why? - D.R. Giacobbe (Italy)
11.50 - 12.05	s better to start with vancomycin or fidaxomicin in CDI infections? - M. Valerio Minero (Spain)
12.05 - 12.20	The role of old antibiotics in empirical treatment - G. Dimoupoulos (Greece)
	LECTURE The future of BL/BLIs in Gram-negative infections Play video Speaker: M. Bassetti (Italy)
	SYMPOSIUM COVID-19 Play video Chairs: C. Mastroianni, J.F. Timsit (France)
14.45 - 15.00	Current epidemiological and virological situation of COVID-19 - J.F. Timsit (France)
15.00 - 15.15	Why does COVID-19 remain a problem for our patients? - C. Mussini (Italy)
15.15 - 15.30	Antiviral treatment for COVID-19: state of the art - C. Dentone (Italy)
15.30 - 15.45	Persistent viral shedding in covid-19: clinical implications, established facts, and areas of uncertainty - A. Gori (Italy)
15.45 - 16.00	What to expect in the future: new therapeutic strategies to fight COVID-19 A. Soriano (Spain)
	SYMPOSIUM Difficult and complicated viral infections Play video Chairs: A.M. Cattelan (Italy), A. Gori (Italy)
16.35 - 16.50	Choosing art: key considerations and long-term health implications for people living with HIV - - C. Mussini (Italy)
16.50 - 17.05	How I manage refractory/resistant CMV Infection in SOT patients? - M. Peghin (Italy)
17.05 - 17.20	Changes in infectious diseases in a changing world: new epidemiology and clinical impact of dengue and arboviruses - C. Sepulcri (Italy)
17.20 - 17.35	Mpox virus: a flash in the pan or still a problem? - L. Taramasso (Italy)